Therapeutic Modalities
Small Molecules
Small Molecule Drugs: The Cornerstone of Future Pharmaceutical Innovation
Small molecule drugs have been the dominant form in pharmaceuticals to date, and even as modalities diversify in the future, they are expected to continue to comprise the majority of newly approved drugs. This is because they are economical for medical use and convenient for patients. In other words, small molecule drugs are less expensive to produce compared to others and can be administered in flexible ways such as orally, sublingually, or by injection, which is patient friendly. Furthermore, in the field of central nervous system diseases, small molecules with the potential to penetrate the brain are a modality that should be further developed. Therefore, the discovery of small molecule drugs will continue to play an important role in the future.
Streamlining Drug Discovery with Integrated Expertise
Axcelead offers a comprehensive platform that enables one-stop drug discovery for small molecule drugs, effectively addressing key challenges from target identification to IND. Through its integrated drug discovery approach, Axcelead leverages expertise across chemistry, biology, pharmacology, DMPK, and safety, working in synergy to advance projects efficiently. This streamlined process ensures drug discovery can be completed in the shortest possible time.
Accelerating Innovation with Data and AI Technologies
Axcelead provides access to data from approximately 1,000 projects across multiple therapeutic areas, including 180+ projects with curated, ready-to-go compounds and assays known as IND-Enabling Projects. By utilizing these resources, Axcelead quickly and efficiently advances drug discovery projects to candidate molecules. Additionally, Axcelead’s cutting-edge computational chemistry and AI/ML technologies further accelerate progress, driving innovation in drug discovery research.